Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Time to Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) gapped up prior to trading on Thursday . The stock had previously closed at $8.28, but opened at $8.69. Gyre Therapeutics shares last traded at $8.80, with a volume of 161,586 shares.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on GYRE shares. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. Finally, Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Stock Down 1.2%

The firm’s 50 day simple moving average is $7.84 and its 200-day simple moving average is $7.78. The company has a market capitalization of $788.00 million, a PE ratio of 272.76 and a beta of 1.97.

Institutional Investors Weigh In On Gyre Therapeutics

A number of large investors have recently modified their holdings of GYRE. SBI Securities Co. Ltd. lifted its position in shares of Gyre Therapeutics by 87.9% during the second quarter. SBI Securities Co. Ltd. now owns 232,299 shares of the company’s stock worth $1,707,000 after purchasing an additional 108,670 shares in the last quarter. State Street Corp grew its stake in shares of Gyre Therapeutics by 10.7% during the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after acquiring an additional 19,472 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after acquiring an additional 7,361 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Gyre Therapeutics in the fourth quarter worth about $77,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Gyre Therapeutics by 72.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 31,108 shares of the company’s stock valued at $220,000 after purchasing an additional 13,074 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.